Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.17 Average Price Target from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $32.1667.

A number of equities analysts have commented on CPRX shares. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Finally, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th.

Catalyst Pharmaceuticals Trading Up 0.1%

NASDAQ:CPRX opened at $31.25 on Friday. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 0.91 and a beta of 0.72. The firm’s fifty day simple moving average is $26.55 and its 200 day simple moving average is $24.57. Catalyst Pharmaceuticals has a twelve month low of $19.05 and a twelve month high of $32.56.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Catalyst Pharmaceuticals by 7.8% in the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock worth $161,224,000 after purchasing an additional 502,235 shares during the last quarter. Deerfield Management Company L.P. increased its position in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Catalyst Pharmaceuticals by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after purchasing an additional 433,318 shares during the last quarter. Fundsmith LLP increased its position in shares of Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after purchasing an additional 654,721 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).